R&D Jennifer Schneider’s insights on immunotherapy at JP Morgan ... Jonah Comstock caught up with Jennifer Schneider, CEO of Centauri Therapeutics, in San Francisco in January during the JP Morgan Healthcare Conference
News JPM: AbbVie pays $650m upfront for RemeGen cancer drug AbbVie joins the ranks of companies developing cancer drugs that target both PD-1 and VEGF, via a $5.6bn licensing deal with China's RemeGen.
Sales & Marketing Sponsored How to meet your physicians where they are online A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.